12-21-2016 10:49 AM CET - IT, New Media & Software

Detailed Study on Merck KGaA / Merck Serono Partnering Deals and Alliances during 2010 to 2016

Press release from: Market Research Hub
Market Research Hub
Market Research Hub
Albany, New York, December 20, 2016: A new pharmaceutical report has been added to the vast archive of Market Research Hub’s repository. The report is entitled “Merck KGaA / Merck Serono Partnering Deals and Alliances during 2010 to 2016”. This report provides all the information you require to gain a better understanding of Merck KGaA and its M&A, partnering interests and activities over the past five years.

Request for Sample Report: www.marketresearchhub.com/enquiry.php?type=S&repid=871912

Initially, with around 6 chapters, the report discusses top deals by value, submitting opportunities, partnering and M&A directory since 2010 to present along with forthcoming partnering events. One of the key aspects of partnering deals is finding those companies that are potential partners for the commercialization of the next generation of therapies as developed by innovative bio pharma R&D companies. The report firstly provides a brief introduction of the leading company Merck KGaA/Merck Serono. Merck Serono is the biopharmaceutical division of Merck KGaA, a global pharmaceutical and chemical company headquartered in Darmstadt, Germany. They discover, develop, manufacture and market prescription medicines of both chemical and biological origin in professional indications. Merck also employs a collaborative R&D model, partnerships with academic, research institutions and pharma companies to bring new therapies for the patients.

In 2015, a company named Pfizer Inc. announced that it has entered into an agreement with Merck KGaA to develop an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a possible treatment for multiple types of cancer. Pfizer and Merck KGaA will explore the therapeutic potential of the anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer’s and Merck KGaA’s extensive portfolio of approved and investigational oncology therapies. In addition to internal research & development activities, Merck Serono is also involved in openly funded collaborative research projects with other industrial and academic partners.

In the next section, the profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering activity, partnering interests, according to deal type, industry sector, phase of development and therapy area. Furthermore, every deal record links to an online, live version of the deal record at the current agreements deals & alliances database. Where available, deal records also comprise the contract document as revealed at the SEC (Security exchange commission).

Browse Full Report with TOC: www.marketresearchhub.com/report/merck-kgaa-merck-serono-...

Through this report, the reader gets an idea of who is leading or succeeding in deal making, as it contains details about the diagnostics dealmaker companies.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : www.marketresearchhub.com
Follow Us- www.linkedin.com/company/market-research-hub

This release was published on openPR.
News-ID: 398547 • Views: 506
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: